Abstract: Since the discovery of thienamycin (1) in 1976, many studies on the synthesis and structure-activity relationships of parenteral-use drugs have been done and several carbapenems, imipenem (2), panipenem (3), and meropenem (7), have been marketed.
INTRODUCTION
Since the discovery of thienamycin (1) in 1976, carbapenem compounds have provided a new generation of β-lactam antibiotics highly potent against a broad range of bacterial species [1] [2] [3] [4] . Compound 1, however, could not be marketed due to chemical and biological instability. To overcome these problems, many groups started to develop stable compounds and ways of synthesizing thienamycin because enzymatic production was not effective. Under these circumstances, imipenem (2) containing cilastatin (4) as an inhibitor of renal dehydropeptidase-I (DHP-I) was marketed by Merck & Co., Inc. Next, the Sankyo group marketed panipenem ( 3) containing betamipron (5) for the alleviation of nephrotoxicity.
In 1984, the Merck research group reported an attractive 1β-methylcarbapenem (6) [5] . Compound (6) had potential as a candidate for a new generation of antibiotics because it could directly resist metabolism by renal DHP-I without additives like cilastatin (4) . The discovery of 6 accelerated the development of stereoselective carbon-carbon bond formation methods for the construction of chiral C-1 on 1β-substituted carbapenems 42] . From these studies, meropenem (7) developed by the Sumitomo group was marketed as the first 1β-methylcarbapenem. After that, *Address correspondence to this author at the Medical Research Laboratories, Wyeth Lederle (Japan) Ltd., 1-6-34, Kashiwa-cho, Shiki-shi, Saitama 353-8511, Japan; E-mail: KumagaT@labs.wyeth (8) , MK-826 ( 9), S-4661 (10), and ER-35768 (11) underwent clinical trials [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . All these compounds are for parenteral use.
Carbapenem compounds have long been considered unstable even in neutral conditions, much less in gastric juice and/or intestinal juice. However, recently, orally active 1β-methylcarbapenems including tricyclic carbapenems have been reported. Some of them, GV-118819 (12) , CS-834 (13), L-084 (14) , and DZ-2640 (15) , are undergoing clinical trials and their pharmacokinetics in human have been demonstrated. In addition, CL 191,121 (16) and its derivatives 47, 48, 49 have been undergoing preclinical studies. This review focuses on oral 1β-methylcarbapenems.
THE SYNTHESIS OF β-METHYLAZETIDIN-2-ONE
Carbapenem chemistry advanced rapidly with the development of practical methods of synthesizing 4-acetoxyazetidin-2-one (17) and β-methylazetidine-2-one (18) in the 1980s. With the establishment of a method of producing 6 by Shih et al. in 1984 [5] , many research groups started studying highly stereoselective synthesis of 18 which The Merck group and ourselves reported on a highly diastereoselective alkylation at the C-4 position of 4-acetoxyazetidin-2-one (17) [7, 8] . Since then, effective and industrial ways to prepare 17 and 18 have been reported [42, 43, 44] .
Recently, the Takasago group developed an aldol type reaction from 17 to 18 using magnesium enolate of chiral propanoyl sulfone amide (19) (Fig. 1) [45] .
CONSTRUCTION OF A 1β-METHYLCARBAPENEM SKELETON
The formation of a 1β-methylcarbapenem skeleton from 18 has been accomplished by three different approaches (Fig.  2) . The intramolecular carbene insertion reaction, Wittig type reaction, and Dieckmann type reaction. First, a C3-N4 bond was formed by the intramolecular carbene insertion of diazo compound (21) in the presence of catalytic rhodium complex [5] . In 1992, we succeeded in preparing 23 (R 1 = pnitrobenzyl) as crystals which are stable and a useful starting material for exploration of novel 1β-methylcarbapenem Recently, a C3-N4 bond formation utilizing iodonium ylide and C2-C3 bond formation using Eschenmoser sulfide contraction were reported (Fig. 3) . Interesting results were obtained from the C3-N4 bond formation by the carbene insertion reaction using iodonium ylide. The use of an acidic catalyst in this reaction dominantly gave the 3S-form of 29 (94% yield). On the other hand, the use of a rhodium catalyst dominantly gave the 3R-form of 29 (86% yield) [57] . Regarding the C2-C3 bond formation, thiazinone (30) was used as a key intermediate to obtain 31 [58] .
CONSTRUCTION OF THE TRICYCLIC CARBA-PENEM SKELETON
Tricyclic carbapenems, which have a broad spectrum of activity against gram-positive and gram-negative bacteria and good stability in the presence of human DHP-I, were discovered by the Glaxo Welcome research group. GV 104326 (35) , whose prodrug ester is undergoing clinical trials, was selected as a clinical candidate based on the structure-activity relationship [59, 60] .
Highly diastereoselective synthesis of a key intermediate (34) for the construction of the tricyclic carbapenem skeleton has been achieved by the reaction of acetoxyazetidin-2-one (17) with homochiral cyclohexenyl boranes (32), cyclohex-2-enyldimethylsilyl chloride (36) , or racemic β-ketoester (38) (Fig. 4) [60, 61, 62] .
As a further study of the tricyclic carbapenems, some thia-or oxa-or aza-analogs containing a sulfur, oxygen, or nitrogen atom in the cyclohexane ring have also been synthesized ( Fig. 5) and their antibacterial activities have been reported [64, 65, 66, 67] .
DEVELOPMENT OF ORAL CARBAPENEMS
Since the discovery of thienamycin in 1976, numerous carbapenems have been developed for parenteral use, but not for oral administration because carbapenems have been considered unstable even under neutral conditions. In addition, β-lactam antibiotics are known to be difficult to absorb from the intestine.
In general, oral drugs are absorbed by either passive transport through phospholipid membranes or active transport through a carrier mechanism. Recently, oral carbapenems with a double ester or a peptidic structure which are chemically and biologically stable have been reported.
GV-118819 (12)
This is the first tricyclic carbapenem and has been developed as a prodrug ester by the Glaxo Welcome group. The structure-activity relationships of GV-104326 (35) and its related compound have been disclosed [60] . Some of the results are shown in Table 1 .
GV-104326 (35) showed a broad antibacterial spectrum with high potency, resistance to β-lactamases and good stability in the presence of renal dehydropeptidase-I. Comparative MICs were determined for 35 against 415 clinical isolates. The antibacterial activity against gram- positive bacteria of 35 was slightly inferior to that of imipenem. Against gram-negative bacteria except P. aeruginosa, 35 possessed activity similar to imipenem. 35 was resistant to clinically relevant β-lactamases and was lethal to susceptible bacteria. 35 showed binding affinity for PBP 2 and 4 of S. aureus and for PBP 1a and 2 of E. coli [59] .
The pharmacokinetics of GV-118819 (12) following single oral administration at two dose levels to six healthy male volunteers have been reported [63] . Mean peak 
CS-834 (13)
This compound has been developed by the Sankyo group and is now in clinical trials. They found that R-83201 (42) had a good balance of antibacterial activity and biological stability. They also evaluated the urinary recovery of some prodrug esters of R-83201 (42) after oral administration in mice. Among them, two prodrug esters of 42, the pivaloyloxymethyl ester (13) and the 1-methylcyclohexylcarbonyloxymethyl ester (43) , exhibited excellent urinary recoveries of 47% and 55%, respectively. The pharmacokinetics of these two compounds in dogs after oral administration were compared to find the best prodrug ester ( Table 2 ) [68] . Then, the chemical stability of CS-834 was confirmed to be good in a neutral phosphate buffer solution (degradation rate constant: 0.031 at pH 6.86) [69] . Finally CS-834 was selected for further evaluation.
CS-834 (13) was administered orally for an evaluation of safety and pharmacokinetics to healthy male volunteers at single doses of 50, 100, 200, and 400 mg and at a multiple dose of 150 mg three times a day for 7 days. In the fasted state, the concentration of R-95867 (41) in plasma reached maximum levels from 1.1 to 1.7 h following the oral administration of CS-834. Maximum concentrations of R-95867 (41) in plasma of 0.51, 0.97, 1.59, and 2.51 µg/ml were attained after administration of CS-834 (13) at doses of 50, 100, 200, and 400 mg, respectively. The half-lives were about 0.7 h. The AUCs were proportional to the doses in the range from 50 to 400 mg. The cumulative urinary excretion ranged from 27 to 34% of the dose until 24 h after the drug administration. No influence of food intake on the pharmacokinetics of R-95867 (41) was observed.
The pharmacokinetics in the multiple dose study (150 mg three times a day for 7 days) were almost the same as those obtained in the single dose study [70] . 
L-084 (14)
We discovered a novel and characteristic 1β-methylcarbapenem, L-084 (14) , for oral administration. L-084 (14) and L-036 (44), the active form of L-084, have many advantages over other β-lactam compounds, especially in chemical and biological stability, antibacterial activity, and absorption ratio. L-084 is undergoing clinical trials.
3-1. Structure-Activity Relationships [71]
For the purpose of developing an oral carbapenem having unique characteristics, several kinds of compounds were synthesized in conventional ways and evaluated for their activity. The 1β-methylcarbapenems possessing an Nsubstituted azetidinylthio group as the C-2 side chain showed excellent antibacterial activity against gram-positive and gram-negative bacteria except Pseudomonas aeruginosa ( Table 3) . The antibacterial activity of L-036 (44) was superior to that of related compounds. 
3-2. Pharmacokinetics of Prodrug Esters of L-036 in Animals
In order to optimize the oral absorption of L-036 (44), various prodrug esters were prepared in conventional ways [68, 71] and were orally administered to rats ( Table 4) . L-084 (14) was selected for further evaluation because of its chemical and biological stability and high bioavailability in animals.
3-3. Chemical and Biological Properties of L-084 and L-036
The conformation of the C6-hydroxyethyl group of L-036 (44) determined by X-ray analysis is similar to that of biapenem (8) (44), meanwhile, is most stable in solution at pH 6 (degradation rate constant: 0.011). These facts indicate that L-084 would be fairly stable during passage through the stomach and that L-036 delivered to the infection focus, considered to be weakly acidic, would be very effective due to its good stability in a weak acid solution.
The resistance to human renal dehydropeptidase-I is higher than that of meropenem (7) which is a 1β-methylcarbapenem.
3-4. In Vitro Antibacterial Activity of L-036, an Active Metabolite of L-084 [75]
Antibacterial activities of L-036 (44) against clinical isolates of gram-positive and gram-negative bacteria were examined. The clinical isolates of bacteria were S. aureus (n = 106, MSSA; 53, MRSA; 53), S. epidermidis (n = 52), S. pneumoniae (n = 52, PSSP; 24, PRSP; 28), S. pyogenes (n = 19), E. coli (n = 50), K. pneumoniae (n = 53), M. catarrhalis (n = 53), E. cloacae (n = 53), P. mirabilis (n = 53), S. marcescens (n = 54), and P. aeruginosa (n = 5). The activities of L-036 against clinical isolates of gram-positive bacteria were slightly superior to those of imipenem. On the other hand, the activities against clinical isolates of gramnegative bacteria were stronger than those of levofloxacin except for H. influenzae and P. aeruginosa. The activity of L-036 against H. influenzae was stronger than that of imipenem.
L-036 also showed potent activities against various β-lactamase-producing strains excluding carbapenemase producers. L-036 exhibited high binding affinities for PBP 1A, -1B, -2A/2X, -2B, and 3 of penicillin resistant S. pneumoniae (PRSP) and for PBP 1B, -2, -3A, and -3B of H. influenzae. 
3-5. Pharmacokinetics of L-084 in Human [76]
L-084 (14) was administered orally to healthy male volunteers at single doses of 25, 50, 100, and 200 mg and at a multiple dose of 100 mg and 200 mg three times a day for 7 days as the equivalent of L-036 (44) to investigate its safety and pharmacokinetics. In addition, the effect of food intake on the absorption was examined at a dose of 75 mg. The mean maximum concentrations of L-036 in plasma (Cmax) ranged from 1.27 (25 mg dose) to 5.93 µg/ml (200 mg dose) and were reached from 0.5 to 0.7 h following the drug administration. The half-lives were from 0.3 to 0.5 h. The areas under the concentration-time curve (AUCs) were proportional to the doses in the range from 25 to 200 mg. The accumulative urinary recoveries (0 to 24 h) of L-036 were in the range of 54 to 73%. The level of the hydrolyzed product of the β-lactam ring of L-036 was about 10% in urine as an inactive metabolite. No effect of food intake was observed. The multiple-dose study showed no drug accumulation in the body. No significant adverse event was observed.
L-036 (44) reaches a fairly high Cmax quickly after oral administration of L-084 (14) which shows very high bioavailability, is excreted rapidly. Taking the long post antibiotic effect of L-036 into consideration, L-084 would afford the maximum effect at minimum amounts.
DZ-2640 (15)
This compound was found by the Dai-ichi group [77] . DU-6681 (45) having a chiral bicyclic imidazole ring as the C-2 substituent showed potent and broad antibacterial activity except against P. aeruginosa. The structure-activity relationships of the compounds having different bicyclic imidazole ring systems and of their optical isomers shown in Fig. (6) were examined.
It was observed that the bicyclic imidazole ring system attached to the C-2 position of 1β-methylcarbapenem influenced the stability in the presence of dehydropeptidase-I and the pharmacokinetics in rats after oral administration of each pivaloyloxymethyl ester ( Table 5) .
After the selection of DU-6681 (45) based on these results, several prodrug esters were prepared in order to optimize the oral absorption ( Table 6) . DZ-2640 (15) , the pivaloyloxymethyl ester of DU-6681 (45), was then selected for further study.
The antibacterial activity of DU-6681a (46) , sodium salt of a parent compound of DZ-2640 (15), against clinical isolates of gram-positive and gram-negative bacteria was studied [78] . The MIC90s of DU-6681a for methicillinsusceptible S. aureus (MSSA, n = 27), methicillin-resistant S. aureus (MRSA, n = 19), and S. epidermidis (n = 22) were 0.01, 25, and 12.5 µg/ml, respectively. The MIC90s for S. pyogenes (n = 25) and penicillin-susceptible (n = 18) and penicillin-resistant S. pneumoniae (n = 21) were 0.006, 0.025, and 0.20 µg/ml, respectively. The MIC90s for H. influenzae including β-lactamase-producing strains (n = 38) was 0.02 µg/ml. DU-6681a (46) was stable on exposure to various types of β-lactamases except S. maltophilia type 3 enzyme and showed potent antibacterial activity against β-lactamase-producing strains except S. maltophilia and P. aeruginosa. In addition, DU-6681a (46) is much more resistant to renal dehydropeptidase-I than imipenem.
The pharmacokinetics of DZ-2640 (15) in the mouse, rat, dog, and monkey were investigated and a species difference was observed in the Cmax and excretion rate (the mouse had the highest Cmax and the dog the lowest urinary recovery rate) [79] .
The pharmacokinetics of DZ-2640 (15) in healthy volunteers were investigated after administration of single doses at 25, 50, 100, 200, and 400 mg (as the equivalent of DU-6681) in the fasted state. The effect of food intake on the bioavailability of DZ-2640 was examined [80] . The mean maximum concentrations of DU-6681 in plasma (Cmax) ranged from 0.263 µg/ml (25 mg dose) to 2.489 µg/ml (400 mg dose) and were reached within 1.5 h of the drug On administration of 400 mg, the AUC and Cmax did not increase proportionally. The cumulative urinary recoveries (0 to 24 h) were in the range of 32 to 45%. Food intake significantly decreased the AUC, but there was no effect on the Cmax, Tmax, half-life, or cumulative urinary recovery.
CL 191,121 (16) and the Peptidic Derivatives
This study has been done by the Wyeth-Ayerst group and is in the pre-clinical stage.
The compound, CL 191,121 (16) , possessing an aminomethyltertahydrofuranylthio group as the C-2 substituent on 1β-methylcarbapenem, has a broad spectrum and potent antibacterial activities [81, 82] . It was found that CL 191,121 (16) demonstrated moderate oral activity against an E. coli infection in mice [82, 83] . In order to improve the bioavailability of CL 191,121 (16), they made use of a peptide-mediated transport system and synthesized various compounds in which amino acids were introduced to the aminomethyltetrahydrofuranyl side chain at the C-2 position [84] .
The resulting peptidic prodrugs with L-amino acids showed improved efficacy after oral administration in mice. Peak levels of 4.8, 7.4, and 9.2 µg/ml of CL 191,121 were observed in the serum of mice given oral doses of 20 mg/kg of 121-Ala (47), 121-Val (48), and 121-Ile (49), respectively. The levels of peptidic carbapenems, 47, 48, and 49, in serum were below the limit of detection at all time points after the oral administration of an equivalent dose of CL 191,121 (16) . In contrast, the oral activity of D-amino acid derivatives was less than that of CL 191,121. From these results, it was concluded that D-amino acid derivatives of 16 could not be absorbed and L-amino acid derivatives of 16 increase the bioavailability [83] .
CL 191,121 (16), 121-Ala (47), 121-Val (48), and 121-Ile (49) exhibited good resistance to hydrolysis by renal dehydropeptidases of the mouse, rat, hog, and human [85] . Double ester prodrugs of CL 191,121 (16) were also prepared in order to facilitate absorption through the phospholipid membranes by eliminating the ionic nature and increasing the lipophilicity of 16. The bis-double ester derivatives demonstrated a more enhanced oral activity than the mono-double ester derivatives. The oral activity of the bis-double ester derivative (50: R 1 = -CH(CH 3 )OCO(CH 3 ) 3 , R 2 = -CH 2 OCO 2 CH 2 CH 3 ) was the same as that of 121-Val (48), peptidic prodrug [86] . Further progress in the development of peptidic prodrugs of 16 is expected.
Patents for bis-double ester derivatives of meropenem (7) were published in 1998 and 1999 [87] . To our knowledge, there are no reports available on these compounds.
CONCLUSION
An orally active carbapenem has been awaited since the discovery of thienamycin in 1976. However, many problems Recently, 1β-methylcarbapenems without these problems have been developed and their chemical and biological properties, as well as pharmacokinetics in laboratory animals and humans reported. Table 7 shows the pharmacokinetic parameters after oral administration to humans reported to date. However, no orally active carbapenem is as yet on the market. The first thing to be done is to improve the chemical stability. The second thing is to improve the bioavailability. The last thing is to establish a method of low cost production. The search for an orally active carbapenem is still in the initial stage, and great progress is hoped for in the future. 
